Skip to main content
placeholder image

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2021

Citation


  • Ozguroglu, M., Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 39(15_suppl), 9085. doi:10.1200/jco.2021.39.15_suppl.9085

Web Of Science Accession Number


Start Page


  • 9085

End Page


  • 9085

Volume


  • 39

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2021

Citation


  • Ozguroglu, M., Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 39(15_suppl), 9085. doi:10.1200/jco.2021.39.15_suppl.9085

Web Of Science Accession Number


Start Page


  • 9085

End Page


  • 9085

Volume


  • 39

Issue


  • 15_suppl

Place Of Publication